Meissner H O, Mscisz A, Reich-Bilinska H, Mrozikiewicz P, Bobkiewicz-Kozlowska T, Kedzia B, Lowicka A, Barchia I
Faculty of Health Studies, Charles Sturt University & Therapeutic Research International, GPO Box 4792, Sydney 2001, Australia;
Int J Biomed Sci. 2006 Dec;2(4):375-94.
This is the second, conclusive part of the clinical study on clinical responses of early-postmenopausal women to standardized doses of pre-Gelatinized Organic Maca (Maca-GO). Total of 34 Caucasian women volunteers participated in a double-blind, randomized, four months outpatient crossover configuration Trial. After fulfilling the criteria of being early-postmenopausal: blood Estrogen (E2<40 pg/ml) and Follicle Stimulating Hormone (FSH>30 IU/ml) at admission, they were randomly allocated to Placebo (P) and Maca-GO (M) treatments (2 groups of 11 participants each). Two 500 mg vegetable hard gel capsules with Maca-GO or Placebo powder were self-administered twice daily with meals (total 2 g/day). At admission and follow-up monthly intervals, body mass index (BMI), blood pressure, levels of gonadal, pituitary, thyroid and adrenal hormones, lipids and key minerals were measured. Bone markers were determined after four months M and P use in 12 participants. Menopausal symptoms were assessed according to Greene's Score (GMS) and Kupperman's Index (KMI). Data were analyzed using multivariate technique on blocs of monthly. Results and canonical variate technique was applied to GMS and KMI matrices. Two months application of Maca-GO stimulated (P<0.05) production of E2, suppressed (P<0.05) blood FSH, Thyroid (T3) and Adrenocorticotropic hormones, Cortisol, and BMI, increased (P<0.05) low density lipoproteins, blood Iron and alleviated (P<0.001) menopausal symptoms. Maca-GO noticeably increased bone density markers. In conclusion, Maca-GO applied to early-postmenopausal women (i) acted as a toner of hormonal processes along the Hypothalamus-Pituitary-Ovarian axis, (ii) balanced hormone levels and (iii) relieved symptoms of menopausal discomfort, (hot flushes and night sweating in particular), thus, (iv) exhibited a distinctive function peculiar to adaptogens, providing an alternative non-hormonal plant option to reduce dependence on hormone therapy programs (HRT).
这是一项关于绝经后早期女性对标准化剂量的预糊化有机玛咖（Maca-GO）临床反应的临床研究的第二部分，也是结论部分。共有34名白人女性志愿者参与了一项为期四个月的双盲、随机、门诊交叉配置试验。在满足绝经后早期的标准后：入院时血液雌激素（E2<40 pg/ml）和促卵泡激素（FSH>30 IU/ml），她们被随机分配到安慰剂（P）组和Maca-GO（M）组进行治疗（每组11名参与者）。每天两次随餐自行服用两粒含Maca-GO或安慰剂粉末的500毫克植物硬胶囊（每天总计2克）。在入院时以及每月随访时，测量体重指数（BMI）、血压、性腺、垂体、甲状腺和肾上腺激素水平、血脂以及关键矿物质。在12名参与者使用M和P四个月后测定骨标志物。根据格林评分（GMS）和库珀曼指数（KMI）评估绝经症状。使用多变量技术按月分组分析数据。结果并将典型变量技术应用于GMS和KMI矩阵。应用Maca-GO两个月刺激了（P<0.05）E2的产生，抑制了（P<0.05）血液FSH、甲状腺（T3）和促肾上腺皮质激素、皮质醇以及BMI，增加了（P<0.05）低密度脂蛋白、血液铁含量，并缓解了（P<0.001）绝经症状。Maca-GO显著增加了骨密度标志物。总之，应用于绝经后早期女性的Maca-GO（i）作为下丘脑 - 垂体 - 卵巢轴激素过程的调理剂，（ii）平衡激素水平，（iii）缓解绝经不适症状（特别是潮热和盗汗），因此，（iv）表现出适应原特有的独特功能，提供了一种替代的非激素植物选择，以减少对激素治疗方案（HRT）的依赖。
